GlassScriptPhysician profile
Lori Wilson
NPI 1235467994
$9,354.55
in general payments reported to CMS, 2019-2025
39 companies · $2,882 in 2025
The $2,882 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.23 · 2022: $1,513 · 2023: $2,076 · 2024: $2,873 · 2025: $2,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,725 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,724.90 |
| Education | $105.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,160.84 | 2022-2025 | |
| Janssen Biotech, INC. | $1,546.17 | 2022-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $859.88 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $436.74 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $405.86 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Aimmune Therapeutics, INC. | $334.13 | 2024-2025 | Vowst, Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.16 | 2023-2025 | Xifaxan |
| Lilly USA, LLC | $219.11 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $169.26 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $149.69 | 2023-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $145.98 | 2024-2025 | Voquezna |
| Genzyme Corporation | $133.61 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.33 | 2022-2025 | Caplyta |
| Evoke Pharma, INC. | $125.00 | 2022 | |
| Intercept Pharmaceuticals, INC. | $120.65 | 2022-2025 | Ocaliva |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $107.95 | 2025 | |
| Madrigal Pharmaceuticals | $104.67 | 2025 | Rezdiffra |
| Neuraxis, INC. | $85.56 | 2025 | |
| Celgene Corporation | $84.12 | 2023 | Zeposia |
| Novo Nordisk INC | $80.69 | 2023-2025 | Wegovy |
| Ardelyx, INC. | $75.17 | 2024-2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $49.46 | 2023-2025 | Idacio |
| Regeneron Healthcare Solutions, INC. | $46.96 | 2024-2025 | Dupixent |
| Braintree Laboratories, INC. | $45.21 | 2022-2024 | Suflave, Sutab |
| Pharmacosmos Therapeutics INC. | $44.19 | 2023-2024 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $43.67 | 2024 | Iqirvo |
| Janssen Pharmaceuticals, INC | $41.88 | 2022-2023 | Spravato |
| Intra-Sana Laboratories | $40.04 | 2022 | |
| Merck Sharp & Dohme LLC | $38.67 | 2023-2024 | Dificid, Zinplava |
| Mallinckrodt Hospital Products INC. | $29.88 | 2024 | Terlivaz |
| Astellas Pharma US INC | $29.40 | 2023-2025 | Veozah, Xospata |
| E.R. Squibb & Sons, L.L.C. | $23.72 | 2024 | Zeposia |
| Organon LLC | $22.80 | 2025 | Renflexis, Hadlima |
| Biohaven Pharmaceutical Holding Company LTD. | $20.98 | 2022 | |
| Celltrion USA INC. | $20.90 | 2024 | Zymfentra |
| Astrazeneca Pharmaceuticals LP | $20.28 | 2023 | Andexxa |
| Bayer Healthcare Pharmaceuticals INC. | $17.93 | 2022 | |
| Axonics, INC. | $17.78 | 2024 | Axonics |
| Esperion Therapeutics, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.